Log in

Relevant bibliographies by topics / Low dose tamsulosin / Journal articles

To see the other types of publications on this topic, follow the link: Low dose tamsulosin.

Journal articles on the topic 'Low dose tamsulosin'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Low dose tamsulosin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dr., Taimoor Ahmed Jataoi Dr. Adeel Mahesar Dr. Javed Altaf Jat *. and Dr. Muhammad Ayyaz. "THE AGE DISTRIBUTION AND EFFECTIVENESS OF LOW DOSE TAMSULOSIN IN LOWER URETERIC STONES." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4386–90. https://doi.org/10.5281/zenodo.1064351.

Full text

Abstract:

Objective: To determine the effectiveness of low dose tamsulosin as a medical expulsive therapy in patients with lower ureteric stones. Patients and Methods: The six months randomized control trial was conducted on all patients with either gender, age range 30-60 years and stone size 4-10 mm in the lower 1/3rd of the ureter determined on ultrasound at tertiary care hospital. Group A patients was offered low dose tamsulosin (0.2 mg) one tablet daily in the morning for a maximum of 4 weeks and group B served as control. The final outcome was measured at the end of 4th week of treatment. Patients

APA, Harvard, Vancouver, ISO, and other styles

2

Arka Banerjee, Pranab Kumar Ghosh, and Hindol Mondal. "Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone." Asian Journal of Medical Sciences 15, no. 7 (2024): 177–81. http://dx.doi.org/10.3126/ajms.v15i7.65415.

Full text

Abstract:

Background: Urolithiasis is a common condition in daily urological practice. Medical Expulsive Therapy (MET) is non-invasive approach for removal of ureteric stone. In MET, alpha-blocker Tamsulosin is commonly used in treating urolithiasis but it does not address the pathology of inflammation presents in such condition. With addition of low dose Deflazacort as anti-inflammatory agent, there may have a potential to improve the pathology and outcome of the treatment. Aims and Objectives: This study aims to find the efficacy of low-dose deflazacort combined with tamsulosin in the MET for distal u

APA, Harvard, Vancouver, ISO, and other styles

3

Lee, Mary. "Tamsulosin for the Treatment of Benign Prostatic Hypertrophy." Annals of Pharmacotherapy 34, no. 2 (2000): 188–99. http://dx.doi.org/10.1345/aph.18263.

Full text

Abstract:

OBJECTIVE: To review the information necessary to assess the efficacy and safety of tamsulosin compared with other adrenergic antagonists for treatment of symptomatic benign prostatic hyperplasia. DATA SOURCES: A search was conducted of Cumulated Index Medicus, January 1993–August 1999, which was restricted to human trials and English-language journals. STUDYSELECTION AND DATAEXTRACTION: Efficacy studies were included if the design was randomized and included a control group. Drug safety was assessed using data from any patient series or controlled study. DATA SYNTHESIS: Tamsulosin, a uroselec

APA, Harvard, Vancouver, ISO, and other styles

4

Mohamed, G. Soliman Ahmed A. Al-Khalifah Ali H. Al-Khalifah Ali R. Al-Amer Ali S. Al-Badan 6brahim F. Mutaki. "CAN EJACULATORY DYSFUNCTION BE RECOVERED BY LOW DOSE TAMSULOSIN WHILE TREATING SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA?" INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES o6, no. 02 (2019): 3813–17. https://doi.org/10.5281/zenodo.2563927.

Full text

Abstract:

<strong><em>Purpose: </em></strong><em>To evaluate the use of low dose Tamsulosin in relieving lower urinary tract symptoms related to benign prostatic symptoms as a tr</em><em>ial</em><em> to increase the drug safety ( in terms of reducing the drug full dose side effects especially retrograde ejaculation) while maintaining its efficacy in relieving the patients' symptoms. <strong>Material and Methods: </strong>This Prospective study was conducted in King Faisal University polyclinic between November 2013 and March 2014. Patients enrolled in this study were suffering from Lower urinary tra

APA, Harvard, Vancouver, ISO, and other styles

5

Dikko, M., and Y. Sarkingobir. "Body Weight Determination and Histological Examination of Livers in Normal Rats Administered with Tamsulosin." Journal of Applied Sciences and Environmental Management 24, no. 8 (2020): 1335–40. http://dx.doi.org/10.4314/jasem.v24i8.5.

Full text

Abstract:

The objective of this study was to investigate histopathology of livers and carry out body weight determination in normal rats administered with tamsulosin. Standard methods and procedures were used in this study. The results were revealed. Pertaining weight, at the 3rd , 6th and 8th weeks of the study, no significant difference (P>0.05) in weight was found in the group of rats treated with carvedilol (positive control), tamsulosin low dose (12μg/kg) and high dose tamsulosin (40μg/kg) compared to normal control group, respectively. Other inter-groups comparisons were not significantly diffe

APA, Harvard, Vancouver, ISO, and other styles

6

Modi, Jenish, Vipul Lad, and Parag Godhani. "Efficacy of Low-Dose Deflazacort with Tamsulosin in the Medical Expulsive Therapy of Distal Ureterolithiasis: A Randomized Controlled Trial." National Journal of Medical Research 14, no. 04 (2024): 103–8. http://dx.doi.org/10.55489/njmr.140420241011.

Full text

Abstract:

Introduction: Distal ureterolithiasis, characterized by stones in the lower ureter, poses significant challenges in clinical management. Medical expulsive therapy (MET) using Tamsulosin is a common non-invasive treatment, but its efficacy can be limited, especially for stones larger than 5 mm. Deflazacort, a corticosteroid with anti-inflammatory properties, may enhance the effectiveness of Tamsulosin by reducing ureteral inflammation and facilitating stone passage. Methods: This prospective, randomized controlled trial enrolled 80 patients with distal ureteral stones <8 mm. Participants wer

APA, Harvard, Vancouver, ISO, and other styles

7

Rahman, Shafiqur, Mohammad Abdul Aziz, Atm Mowladad Chowdhury, Bakhtiar Ahmed, and Mirza Mahbubul Hasan. "Efficacy of Low Daily Dose of Tadalafil as Mono-Therapy for Diabetic Patients With Lower Urinary Tract Symptoms Suggestive of Benign Enlargement of Prostate." Bangladesh Journal of Urology 20, no. 1 (2020): 18–25. http://dx.doi.org/10.3329/bju.v20i1.49602.

Full text

Abstract:

Objective: To assess efficacy of tadalafil or tamsulosin versus placebo for LUTS/BEP. Methods: This was a triple blind randomized control trial (RCT). This study was done on 150 cases of well controlled diabetic patients with LUTS/BEP after screening. The patients were >45 years of age, international prostate symptom score (IPSS) > 13, maximum urine flow rate (Qmax) 10-15 ml/sec. Selected patients were randomized in to 1:1:1 ratio to once-daily tadalafil 5 mg, tamsulosin 0.4 mg, or placebo for 12 weeks. Efficacy measures were assessed by IPSS, Qmax, post-voidal residue (PVR) in ultra-son

APA, Harvard, Vancouver, ISO, and other styles

8

Tareq, AHM Imrul, and Md Sayedul Islam. "To Compare the Efficacy of Tamsulosin, Solifenacin and Combination of Both in the Treatment of Double-J Stent Related Irritative Lower Urinary Tract Symptoms and Low Back Pain." Bangladesh Journal of Urology 23, no. 1 (2020): 48–51. http://dx.doi.org/10.3329/bju.v23i1.50289.

Full text

Abstract:

Background: Stent-associated symptoms can have a significant impact on patient quality of life. Hematuria, urgency, frequency, dysuria, and both bladder and flank pain are the most prevalent symptoms related to indwelling ureteral stents. Among them irritative lower urinary tract symptoms and low back pain are more frequent. Despite the stent related symptoms, because of its importance stent is being kept in situ with varieties of medication. Several alpha-adrenergic blocker and antimuscarinic drugs are used to relief these symptoms like Tamsulosin, Solifenacin, Alphazosin etc. Both Tamsulosin

APA, Harvard, Vancouver, ISO, and other styles

9

Saito, T., T. Minagawa, T. Ogawa, and O. Ishizuka. "Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients." Journal of Clinical Urology 12, no. 3 (2018): 223–27. http://dx.doi.org/10.1177/2051415818817127.

Full text

Abstract:

Objectives: This study was performed to evaluate the effects of addition of tadalafil to tamsulosin in the treatment of brachytherapy patients with lower urinary tract symptoms (LUTS). Methods: Localized prostate cancer patients who developed LUTS after low-dose-rate brachytherapy (LDR-BT) were first treated with alpha-1 blockers (tamsulosin, 0.2 mg per day). Those still suffering from LUTS were additionally treated with phosphodiesterase type 5 inhibitor (tadalafil, 5 mg/day). LUTS was evaluated by the International Prostate Symptom Score (IPSS), IPSS Quality of Life (QOL) score, Overactive B

APA, Harvard, Vancouver, ISO, and other styles

10

Watanabe, Masaki, Satoshi Yamaguchi, Hidehiro Kakizaki, Naoki Hirabayashi, and Hironori Ishida. "Evaluation of Alpha 1 Adrenoceptor Antagonist Dose Increase Therapy: An Essential Strategy for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia." Current Urology 14, no. 3 (2020): 113–21. http://dx.doi.org/10.1159/000499250.

Full text

Abstract:

<b><i>Introduction</i></b>: There have been a number of reports on dose increase therapy (DI-T) with the alpha 1 adrenoceptor antagonists (α1-blockers) naftopidil and tamsulosin for lower urinary tract symptoms associated with benign prostatic hyperplasia. <b><i>Methods and Results</i></b>: The reports on DI-T (naftopidil 75 mg/d, tamsulosin 0.4 mg/d) in non-responders to low-dose initial therapy (LI-T, naftopidil 50 mg/d, tamsulosin 0.2 mg/d) were summarized. In each study, a non-responder was defined as a patient without sufficient improvements

APA, Harvard, Vancouver, ISO, and other styles

11

Sanjay, Parashar, Kumar Saxena Pradeep, Pathak Akshat, and Gupta Hemlata. "Comparative Study of the Stone Expulsion Rate after Treatment with Tamsulosin,Tadalafil and Combination of Tamsulosin and Tadalafil." International Journal of Toxicological and Pharmacological Research 13, no. 7 (2023): 253–60. https://doi.org/10.5281/zenodo.11115497.

Full text

Abstract:

<strong>Objective: </strong>To compare the stone expulsion rate after treatment with tamsulosin, tadalafil and combination of tamsulosin and tadalafil. , the spontaneous passage of stones, the stone expulsion time, episodes of pain and analgesic dose required and side effects of drugs were noted and compared. <strong>Methods: </strong>Study is a hospital-based observational study conducted over a period of 18 months Patients aged ≥18 years presenting with solitary, symptomatic ureteral stone, size of 5-10 mm were grouped into three equal drug groups. Patients was advised drug

APA, Harvard, Vancouver, ISO, and other styles

12

Li, Ning-Chen, Shan Chen, Xue-Hui Yang, Lin-Dong Du, Jian-Ye Wang, and Yan-Qun Na. "Efficacy of Low-Dose Tamsulosin in Chinese Patients with Symptomatic Benign Prostatic Hyperplasia." Clinical Drug Investigation 23, no. 12 (2003): 781–87. http://dx.doi.org/10.2165/00044011-200323120-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Lojanapiwat, B., W. Kochakarn, N. Suparatchatpan, and K. Lertwuttichaikul. "Effectiveness of Low-dose and Standard-dose Tamsulosin in the Treatment of Distal Ureteric Stones: A Randomized Controlled Study." Journal of International Medical Research 36, no. 3 (2008): 529–36. http://dx.doi.org/10.1177/147323000803600318.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Park, Choal Hee, Hyuk Soo Chang, Bong Ryul Oh, et al. "Efficacy of Low-Dose Tamsulosin on???Lower Urinary Tract Symptoms???Suggestive of Benign???Prostatic Hyperplasia." Clinical Drug Investigation 24, no. 1 (2004): 41–47. http://dx.doi.org/10.2165/00044011-200424010-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Mizuno, R., M. Sawada, T. Tanaka, et al. "Comparison of the Efficacy of Low Dose Tadalafil with Tamsulosin against Lower Urinary Tract Symptoms and Sexual Dysfunction after Low Dose Rate Prostate Brachytherapy." International Journal of Radiation Oncology*Biology*Physics 117, no. 2 (2023): e418. http://dx.doi.org/10.1016/j.ijrobp.2023.06.1570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Liu, Y., S. Zhuang, and L. Ma. "MP-19.05: Low-Dose Tamsulosin Improves Clinical Effect of Single Extracorporeal Shock Wave Lithotripsy for Ureteral Calculi." Urology 74, no. 4 (2009): S136. http://dx.doi.org/10.1016/j.urology.2009.07.786.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Kim, J. H., J. Y. Park, M. M. Oh, J. G. Lee, S. S. Kwon, and J. H. Bae. "Treatment satisfaction with low-dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross-sectional survey." International Journal of Clinical Practice 66, no. 12 (2012): 1209–15. http://dx.doi.org/10.1111/j.1742-1241.2012.02985.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Mizuno, R., E. Kikuchi, T. Kosaka, et al. "Comparative study of prophylactic tadalafil or tamsulosin in patients treated wth low dose rate brachytherapy for prostate cancer." European Urology Supplements 18, no. 11 (2019): e3455. http://dx.doi.org/10.1016/s1569-9056(19)34618-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Cha, Woo Heon, Jae Duck Choi, Ki Ho Kim, Young Jin Seo, and Kyungseop Lee. "Comparison and Efficacy of Low-Dose and Standard-Dose Tamsulosin and Alfuzosin in Medical Expulsive Therapy for Lower Ureteral Calculi: Prospective, Randomized, Comparative Study." Korean Journal of Urology 53, no. 5 (2012): 349. http://dx.doi.org/10.4111/kju.2012.53.5.349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Kobayashi, Masayuki, Yukio Naya, Mika Kino, et al. "Low dose tamsulosin for stone expulsion after extracorporeal shock wave lithotripsy: Efficacy in Japanese male patients with ureteral stone." International Journal of Urology 15, no. 6 (2008): 495–98. http://dx.doi.org/10.1111/j.1442-2042.2008.02033.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kim, Jae Heon, Ji Sung Shim, Hoon Choi, Jae Young Park, Soon-Sun Kwon, and Jae Hyun Bae. "Who are suitable for low-dose tamsulosin monotherapy as initial treatment strategy in male patients with lower urinary tract symptoms?" Medicine 97, no. 44 (2018): e12354. http://dx.doi.org/10.1097/md.0000000000012354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kaneko, Tomoyuki, Hisashi Matsushima, Hirohiko Morimoto, Yasuo Tsuzaka, and Yukio Homma. "Efficacy of low dose tamsulosin in medical expulsive therapy for ureteral stones in Japanese male patients: A randomized controlled study." International Journal of Urology 17, no. 5 (2010): 462–65. http://dx.doi.org/10.1111/j.1442-2042.2010.02499.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kim, Sin Wook, Wan Cheol Lee, Ma Tae Kim, et al. "Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia." Korean Journal of Urology 54, no. 10 (2013): 697. http://dx.doi.org/10.4111/kju.2013.54.10.697.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ahmed, Abul-fotouh, Aref Maarouf, Essam Shalaby, Ahmad H. Gabr, Ashraf Shahin, and Ammar Ghobish. "The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia." World Journal of Urology 33, no. 5 (2014): 649–57. http://dx.doi.org/10.1007/s00345-014-1378-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Shim, Sung Ryul, Jae Heon Kim, Hoon Choi, et al. "General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis." Current Medical Research and Opinion 31, no. 2 (2014): 353–65. http://dx.doi.org/10.1185/03007995.2014.980887.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Chandramohan Kandasamy, Kumar Mohan, Alexandar S, and Sivaselvakumar Muthusamy. "Estimation of solifenacin and tamsulosin in rat plasma by LC-MS/MS: Application to a pharmacokinetic study." International Journal of Research in Pharmaceutical Sciences 11, no. 4 (2020): 7083–93. http://dx.doi.org/10.26452/ijrps.v11i4.3829.

Full text

Abstract:

Effectiveness tests using a mixture of solifenacin and tamsulosin include the implementation of a research procedure for precise plasma evaluation of both drugs. For the direct estimation of solifenacin and tamsulosin, high quality liquid chromatography-tandem mass spectrometry in rat plasma (LC-MS / MS) methodology was designed. Extraction during solid phase technique used to obtain solifenacin, tamsulosin, and solifenacin D5, tamsulosin D4 (internal standards; IS) from 100 μL rat plasma. On the Thermo BDS Hypersil C8 (100 X 4.6 mm, 3.5 μm) column under isocratic elution with acetonitrile, ch

APA, Harvard, Vancouver, ISO, and other styles

27

Maldonado-Valadez, Rafael Edgardo, Angel David Valdez-Vargas, José Antonio Alvarez, and Edel Rafael Rodea-Montero. "Efficacy of Adjuvant Tamsulosin for Improving the Stone-Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones: A Randomized Controlled Trial." International Journal of Clinical Practice 2022 (January 31, 2022): 1–8. http://dx.doi.org/10.1155/2022/3757588.

Full text

Abstract:

Introduction. Extracorporeal shock wave lithotripsy (ESWL) is an effective treatment for urolithiasis. Tamsulosin is capable of causing dilation and facilitating the migration of stones. The aim of this study is to evaluate the efficacy of adjuvant treatment with tamsulosin for improving the stone-free rate after a single session of ESWL in the treatment of kidney stones. Methods. This is a randomized, nonplacebo-controlled study with a sample of 60 adults with a single radiopaque kidney stone of 5–20 mm in diameter. After the ESWL session, the patients were divided into two groups. The contro

APA, Harvard, Vancouver, ISO, and other styles

28

Chen, Andrew, and Anselm Wong. "The Role of Angiotensin II in Poisoning-Induced Shock—a Review." Journal of Medical Toxicology 18, no. 2 (2022): 145–54. http://dx.doi.org/10.1007/s13181-022-00885-4.

Full text

Abstract:

Abstract Background Shock in drug poisoning is a life-threatening condition and current management involves fluid resuscitation and vasopressor therapy. Management is limited by the toxicity of high-dose vasopressors such as catecholamines. Clinical trials have shown the efficacy of angiotensin II as an adjunct vasopressor in septic shock. The aim of this review is to assess the use of angiotensin II in patients with shock secondary to drug overdose. Methods Medline (from 1946), Embase (from 1947) and PubMed (from 1946) databases were searched until July 2021 via OVID. Included studies were th

APA, Harvard, Vancouver, ISO, and other styles

29

Shahagadkar, Preksha Vaibhav, and Gnanasekar Munirathinam. "Exploring NCX4040, an Aspirin Derivative, as a Potential Treatment for Benign Prostatic Hyperplasia." Journal of the Endocrine Society 5, Supplement_1 (2021): A765. http://dx.doi.org/10.1210/jendso/bvab048.1556.

Full text

Abstract:

Abstract Benign Prostatic hyperplasia (BPH) is a leading cause of lower urinary tract symptoms which affects men above 50 years of age. Chronic inflammation and abnormal proliferation of stromal and epithelial cells are implicated in BPH disease onset. The symptoms of BPH include back pain and difficulty in emptying bladder. Finasteride, sildenafil and tamsulosin are some of the drugs used to ease difficulty urinating and relax the muscles of the gland. Transurethral resection of the prostate or laser surgery can be performed to treat severe symptoms. However, these therapies have deleterious

APA, Harvard, Vancouver, ISO, and other styles

30

Priti Ankush Mahadik, Priti Ankush Mahadik. "Analytical Method Development and Validation for Estimation of Tamsulosin Hydrochloride by UV-Spectroscopic Method." International Journal of Pharmaceutical Research and Applications 10, no. 3 (2025): 287–95. https://doi.org/10.35629/4494-1003287295.

Full text

Abstract:

Tamsulosin Hydrochloride is a medication primarily used in men to treat the symptoms of an enlarged prostate, also known as benign prostatic hyperplasia (BPH). It belongs to a class of drugs called alpha – blocker. A simple, specific, rapid, precise and accurate UV Spectroscopic method have been developed and validated for determination of Tamsulosin Hydrochloride. Drug showed the absorption maxima at 280 nm and was linear for a range of 10 – 50 µg/ml with a correlation coefficient 0f 0. 9944.The validation of the above proposed method was done by carrying out precision and accuracy studies. T

APA, Harvard, Vancouver, ISO, and other styles

31

Sandoval, Maria L., Irini Youssef, Kujtim Latifi, et al. "Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results." Journal of Clinical Medicine 10, no. 15 (2021): 3396. http://dx.doi.org/10.3390/jcm10153396.

Full text

Abstract:

Background: The use of stereotactic body radiation therapy (SBRT) is widely utilized for treatment of localized prostate cancer. Magnetic-resonance-guided radiotherapy (MRgRT) was introduced in 2014 and has recently been implemented in SBRT for prostate cancer as it provides an opportunity for smaller margins and adaptive daily planning. Currently, the only publications of MRgRT for prostate SBRT describe European clinical experiences which utilized adaptive planning. However, adaptive planning adds significantly to the time required for daily treatment. Objectives: Since prostate SBRT has dem

APA, Harvard, Vancouver, ISO, and other styles

32

Argirovic, Aleksandar, and Djordje Argirovic. "Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?" Vojnosanitetski pregled 70, no. 12 (2013): 1091–96. http://dx.doi.org/10.2298/vsp110620029a.

Full text

Abstract:

Background/Aim. It has been observed that a large number of patients with low urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH)) has been treated with a combination of tamsulosin (TAM) + Serenoa repens (SR) (TAM + SR). The aim of this study was to compare a combination TAM + SR with TAM and SR alone, to see if there was any difference in efficacy and tolerance of each in patients with LUTS/BPH. Methods. In this prospective study patients had to have prostate volume (PV) < 50 mL, International Prostate Symptom Score (IPSS) of 7-18, Quality of Life score (QoLs) > 3, a m

APA, Harvard, Vancouver, ISO, and other styles

33

Gborsong, Cosmos, George A. Asare, Robert A. Ngala, et al. "Assessing the Safety of Combined Therapy, Croton membranaceus and Tamsulosin, in the Self‐Prescribed Treatment Protocol for Benign Prostatic Hyperplasia." Journal of Toxicology 2025, no. 1 (2025). https://doi.org/10.1155/jt/5574491.

Full text

Abstract:

Background: The safety of combining tamsulosin (an allopathic drug) and Croton membranaceus aqueous extract, a medicinal plant for managing benign prostatic hyperplasia (BPH), was investigated.Methods: The roots of CM were used and processed into a water extract by maceration and decoction. Thirty‐five Sprague Dawley rats were divided into seven groups of five rats each. Groups 2–7 were orchidectomy/testosterone injections BPH‐induced. Group 1 was designated as the control group. Group 2 was designated as the model group (untreated). Group 3 was treated with 0.03 mg/kg b.wt. of tamsulosin. Gro

APA, Harvard, Vancouver, ISO, and other styles

34

Lulic, Zrinka, Hwancheol Son, Sang-Bae Yoo, et al. "Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database." BMC Urology 21, no. 1 (2021). http://dx.doi.org/10.1186/s12894-021-00941-1.

Full text

Abstract:

Abstract Objective To assess the use and safety of free combination therapy (dutasteride and tamsulosin), dutasteride monotherapy, or tamsulosin monotherapy in patients with benign prostatic hyperplasia (BPH). Methods This non-interventional retrospective cohort study used claims data from the Korea Health Insurance Review and Assessment-National Patient Sample database. Patients with BPH ≥ 40 years of age receiving combination therapy (dutasteride 0.5 mg and tamsulosin 0.4 mg daily) or dutasteride 0.5 mg, or tamsulosin 0.4 mg daily dose between 2012 and 2017 were included. The frequency, dura

APA, Harvard, Vancouver, ISO, and other styles

35

Sadanala, Madhuri Evangeline, Anuj Deep Dangi, Geetha Rajendran, et al. "Is low‐dose tadalafil better than tamsulosin? An RCT in SWL for solitary upper tract calculi." BJU International, May 2, 2023. http://dx.doi.org/10.1111/bju.16038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Jatoi, Taimur, Javed Altaf, and Muhammad Adeel Mahesar. "Determine the Effectiveness of Low Dose Tamsulosin as a Medical Expulsive Therapy in Patients with Lower Ureteric Stones." Journal of Biomedical Sciences 06, no. 03 (2017). http://dx.doi.org/10.4172/2254-609x.100065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Basani, Gavaskar, Madhusudan Rao Yamsani, and Ramya Sri Sura. "Formulation Development and Evaluation of Multiple Unit Pellet System of Tamsulosin Hydrochloride." Research Journal of Pharmacy and Technology, October 31, 2021, 5319–24. http://dx.doi.org/10.52711/0974-360x.2021.00927.

Full text

Abstract:

The aim of current work was to grow extended release multiple unit pellets of Tamsulosin Hydrochloride, is an alpha-blocker, used for the healing of the symptoms of a prostate gland condition called BPH (benign prostatic hyperplasia) by extrusion- spheronization (E/S) and solution/suspension layering (S/S) method. In the Extrusion-Spheronization, A ratio of 75:25, 67:33, 64:36 Tamsulosin Hydrochloride and Microcrystalline cellulose were mixed for making drug pellets and extended release (ER) coating was performed in fluidized bed processor (FBP) by solution/suspension layering with Ethyl cellu

APA, Harvard, Vancouver, ISO, and other styles

38

Alkhalifah, A., A. Alamer, A. Albadan, A. Alhawaj, I. Mutaki, and M. Soliman. "Can ejaculatory dysfunction be recovered by low-dose tamsulosin in treating patients with symptomatic benign prostatic hyperplasia? – a prospective study." HAMDAN MEDICAL JOURNAL, 2015. http://dx.doi.org/10.7707/hmj.587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Ahmed, Abul-fotouh, Aref Maarouf, Ashraf Shahin, Essam Shalaby, and Ammar Ghobish. "PD23-03 THE IMPACT OF ADDING LOW DOSE ORAL DESMOPRESSIN TO TAMSULOSIN THERAPY FOR TREATMENT OF NOCTURIA SECONDARY TO BENIGN PROSTATIC HYPERPLASIA." Journal of Urology 191, no. 4S (2014). http://dx.doi.org/10.1016/j.juro.2014.02.1840.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Groysman, A. Y., A. Poloju, P. Majety, and T. Abraham. "8208 Unexpected and significant rise in TSH in the setting of Relugolix use." Journal of the Endocrine Society 8, Supplement_1 (2024). http://dx.doi.org/10.1210/jendso/bvae163.2205.

Full text

Abstract:

Abstract Disclosure: A.Y. Groysman: None. A. Poloju: None. P. Majety: None. T. Abraham: None. Background: Relugolix is a gonadotropin-releasing hormone antagonist used as androgen deprivation therapy for metastatic and nonmetastatic castration-resistant prostate cancer that was FDA-approved in December 2020. Common side effects include hot flashes, increased glucose and triglycerides, and decreased hemoglobin. We report a case of Relugolix interference with the absorption of levothyroxine, which has not been reported in the literature. Case: A 79-year-old white man with high-risk, Gleason 9 pr

APA, Harvard, Vancouver, ISO, and other styles

41

Groysman, A. Y., A. Poloju, P. Majety, and T. Abraham. "8208 Unexpected And Significant Rise In TSH In The Setting Of Relugolix Use." Journal of the Endocrine Society 8, Supplement_1 (2024). http://dx.doi.org/10.1210/jendso/bvae163.2121.

Full text

Abstract:

Abstract Disclosure: A.Y. Groysman: None. A. Poloju: None. P. Majety: None. T. Abraham: None. Background: Relugolix is a gonadotropin-releasing hormone antagonist used as androgen deprivation therapy for metastatic and nonmetastatic castration-resistant prostate cancer that was FDA-approved in December 2020. Common side effects include hot flashes, increased glucose and triglycerides, and decreased hemoglobin. We report a case of Relugolix interference with the absorption of levothyroxine, which has not been reported in the literature. Case: A 79-year-old white man with high-risk, Gleason 9 pr

APA, Harvard, Vancouver, ISO, and other styles

42

Vinay, Kumar Nema* Chaitanya Bangari Chandaka Madhu Dr.M.B.Venkatapati Raju. "THE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF DUTASTERIOD & TAMSULOSIN BY USING RP- HPLC." May 17, 2020. https://doi.org/10.5281/zenodo.3831281.

Full text

Abstract:

<em>The method development and validation of Dutasteride and tamsulosin hydrochloride was done by RP-HPLC with  the mobile phase was Acetonitrile: Phosphate buffer mixed in the ratio of 80:20 % v/ v. A Symmetry C18 (4.6 x 150mm, 5m, Make XTerra) column used as stationary phase. The detection was carried out using UV detector at 274 nm. The solutions were chromatographed at a constant flow rate of 0.8 ml/min. the linearity range of Dutasteride and tamsulosin hydrochloride were found to be from 25-125 mg/ml. Linear regression coefficient was not more than 0.999. The values of % RSD are les

APA, Harvard, Vancouver, ISO, and other styles

43

Halmos, Benedek, and Marit Westerterp. "Abstract 16831: Deficiency of Cholesterol Efflux Pathways in Smooth Muscle Cells Enhances Vasoconstriction but Does Not Affect Atherosclerosis." Circulation 148, Suppl_1 (2023). http://dx.doi.org/10.1161/circ.148.suppl_1.16831.

Full text

Abstract:

Smooth muscle cells (SMCs) regulate blood flow distribution via vasoconstriction mediated by α-adrenergic receptors (α-ARs). Plasma membrane cholesterol may affect α 1 -AR signaling, but consequences for SMC-mediated vasoconstriction are unclear. Cholesterol loading promotes SMC to macrophage transition in vitro , which may enhance atherosclerotic plaque vulnerability. However, the role of ATP Binding Cassette A1 and G1 (ABCA1/G1)-cholesterol efflux pathways in SMC-mediated vasoconstriction and atherogenesis remains poorly understood. We generated mice with SMC-specific Abca1/g1 deficiency on

APA, Harvard, Vancouver, ISO, and other styles

44

Koduri, Gouri, Bhaskar Dasgupta, Martyn Barnes, and Sohail Ansari. "11. Accelerated UIP: a special challenge." Rheumatology Advances in Practice 3, Supplement_1 (2019). http://dx.doi.org/10.1093/rap/rkz025.

Full text

Abstract:

Abstract Introduction Interstitial lung disease (ILD) is a progressive fibrotic disease of the lung parenchyma. The lungs are the most common site in rheumatic diseases. ILD may be idiopathic or caused by connective tissue diseases, rheumatoid arthritis, drugs, and infection and radiation therapy. The severity of lung involvement may vary considerably, and, in some cases, it can lead to irreversible fibrosis leading to respiratory failure and eventually death. Although progress has been made in understanding of the disease, there are still significant challenges with the diagnosis and treatmen

APA, Harvard, Vancouver, ISO, and other styles

45

Halmos, B., A. M. La Rose, A. G. Groenen, et al. "Deficiency of Abca1 and Abcg1 mediated cholesterol efflux pathways in smooth muscle cells enhances vasoconstriction but does not affect atherosclerosis." Cardiovascular Research 120, Supplement_1 (2024). http://dx.doi.org/10.1093/cvr/cvae088.152.

Full text

Abstract:

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): VIDI grant from Netherlands Organization of Scientific Research (NWO). Rosalind Franklin Fellowship from the University Medical Center Groningen. Both to Marit Westerterp, PhD Smooth muscle cells (SMCs) regulate blood flow distribution and blood pressure via vasoconstriction mediated by α-adrenergic receptors (α-ARs). Plasma membrane cholesterol may affect α1-AR signaling, but consequences for SMC-mediated vasoconstriction are unclear. Cholesterol loading promotes SMC-to-m

APA, Harvard, Vancouver, ISO, and other styles

46

Altosaar, Katrin, Poornima Balaji, Richard A. Bond, et al. "Adrenoceptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database." IUPHAR/BPS Guide to Pharmacology CITE 2019, no. 4 (2019). http://dx.doi.org/10.2218/gtopdb/f4/2019.4.

Full text

Abstract:

The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [58], see also [180]. Adrenoceptors, α1α1-Adrenoceptors are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. phenylephrine, methoxamine and cirazoline are agonists and prazosin and cirazoline antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bodipy PLprazosin- QAPB) are us

APA, Harvard, Vancouver, ISO, and other styles

47

Altosaar, Katrin, Poornima Balaji, Richard A. Bond, et al. "Adrenoceptors in GtoPdb v.2021.3." IUPHAR/BPS Guide to Pharmacology CITE 2021, no. 3 (2021). http://dx.doi.org/10.2218/gtopdb/f4/2021.3.

Full text

Abstract:

The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [60, 186]. Adrenoceptors, α1 The three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. -(-)phenylephrine, methoxamine and cirazoline are agonists and prazosin and doxazosin antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bod

APA, Harvard, Vancouver, ISO, and other styles

48

Baker, Jillian G., Dianne Perez, Sergio Parra, et al. "Adrenoceptors in GtoPdb v.2024.2." IUPHAR/BPS Guide to Pharmacology CITE 2024, no. 2 (2024). http://dx.doi.org/10.2218/gtopdb/f4/2024.2.

Full text

Abstract:

The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [116, 324]. Adrenoceptors, α1 The three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. -(-)phenylephrine, methoxamine and cirazoline are agonists and prazosin and doxazosin antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and HEAT (BE2254) (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin

APA, Harvard, Vancouver, ISO, and other styles

49

Baker, Jillian G., Poornima Balaji, Richard A. Bond, et al. "Adrenoceptors in GtoPdb v.2023.1." IUPHAR/BPS Guide to Pharmacology CITE 2023, no. 1 (2023). http://dx.doi.org/10.2218/gtopdb/f4/2023.1.

Full text

Abstract:

The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [64, 194]. Adrenoceptors, α1 The three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. -(-)phenylephrine, methoxamine and cirazoline are agonists and prazosin and doxazosin antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bod

APA, Harvard, Vancouver, ISO, and other styles

50

Baker, Jillian G., Poornima Balaji, Richard A. Bond, et al. "Adrenoceptors in GtoPdb v.2023.3." IUPHAR/BPS Guide to Pharmacology CITE 2023, no. 3 (2023). http://dx.doi.org/10.2218/gtopdb/f4/2023.3.

Full text

Abstract:

The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [64, 194]. Adrenoceptors, α1 The three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. -(-)phenylephrine, methoxamine and cirazoline are agonists and prazosin and doxazosin antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bod

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!